Autoantibodies to Joint-Related Peptides Are Associated With Onset of Rheumatoid Arthritis in Presymptomatic Seronegative Individuals - Scorecard - MDSpire
Advertisement
Association of Autoantibodies to Joint-Related Peptides with the Development of Rheumatoid Arthritis in Asymptomatic Seronegative Patients
Clinical Scorecard: Association of Autoantibodies to Joint-Related Peptides with the Development of Rheumatoid Arthritis in Asymptomatic Seronegative Patients
At a Glance
Category
Detail
Condition
Rheumatoid Arthritis (RA)
Key Mechanisms
Autoantibodies to joint-related peptides as predictive markers for RA onset.
Target Population
Asymptomatic seronegative individuals at risk for RA.
Care Setting
Rheumatology clinics and population-based biobanks.
Key Highlights
Autoantibodies can precede RA symptoms by several years.
The SeNe test identifies seronegative early RA patients with high specificity.
JointIDs autoantibodies may predict RA onset in presymptomatic individuals.
Guideline-Based Recommendations
Diagnosis
Utilize biomarkers such as ACPA and RF for RA diagnosis.
Incorporate novel autoantibodies for early detection of RA.
Management
Focus on preventive treatment strategies for at-risk individuals.
Monitoring & Follow-up
Assess autoantibody levels in individuals at risk for RA.
Risks
High levels of ACPA and RF are known risk factors for RA.
Patient & Prescribing Data
Individuals aged 40-60 years from the Umeå cohort.
Precision medicine approaches may tailor treatment based on autoantibody profiles.
Clinical Best Practices
Identify and monitor presymptomatic individuals with elevated autoantibodies.
Use a combination of clinical symptoms and biomarkers for accurate RA diagnosis.
by Outi Sareila, Linda Johansson, Anders Lundquist, Monica Leu Agelii, Lei Cheng, Yibo He, Erik Lönnblom, Maria Andersson, Jan Kihlberg, Anders Esberg, Inger Gjertsson, Rikard Holmdahl, Solbritt Rantapää-Dahlqvist
